According to a recent LinkedIn post from Touchlight, the company plans to attend the ASGCT 2026 meeting in Boston from May 11–15. The post highlights that Touchlight will engage with attendees on its cell‑free DNA technologies, including mbDNA and Custom Circles, positioning these as alternatives to traditional plasmid DNA.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Touchlight is targeting gene and cell therapy developers seeking to accelerate development timelines and address manufacturing bottlenecks. For investors, this presence at a major gene therapy conference may indicate continued business development efforts, potential partnership opportunities, and growing demand for next‑generation DNA manufacturing.
By emphasizing cell‑free DNA production and pipeline acceleration, the content points to Touchlight’s focus on high‑value enabling technologies within gene and cell therapy supply chains. If this visibility translates into new collaborations or expanded customer relationships, it could support revenue growth prospects and reinforce the company’s competitive position in specialized DNA manufacturing.